|
|
Article: Will Clarinex take over the mantle of Claritin?
- Article from:
- Drug Topics
- Article date:
- January 21, 2002
- Author:
CopyrightCopyright Medical Economics Inc. Jan 21, 2002. Provided by ProQuest LLC. (Hide copyright information)
|
Many people will probably see Schering-Plough's newest product, Clarinex (desloratadine), as an attempt to extend the loratadine (Claritin raw train. After all, the first patent on loratadine expires in December of this year, and the company plans to launch desloratadine, another nonsedating antihistamine, this month.
Desloratadine is an active metabolite of loratadine. According to package inserts, the two drugs are quite similar, as would be expected. Both are indicated for treatment of seasonal allergic rhinitis symptoms (both nasal and non-nasal), although loratadine is approved for patients as young as two years. Desloratadine is indicated for patients 12 years and older.
Schering ...